Interpace Biosciences Stock Working Capital
| IDXGDelisted Stock | USD 2.20 0.00 0.00% |
Interpace Biosciences fundamentals help investors to digest information that contributes to Interpace Biosciences' financial success or failures. It also enables traders to predict the movement of Interpace OTC Stock. The fundamental analysis module provides a way to measure Interpace Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Interpace Biosciences otc stock.
Interpace |
Interpace Biosciences OTC Stock Working Capital Analysis
Interpace Biosciences' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Interpace Biosciences Working Capital | (4.21 M) |
Most of Interpace Biosciences' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Interpace Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionAccording to the company's disclosures, Interpace Biosciences has a Working Capital of (4.21 Million). This is 100.99% lower than that of the Health Care Providers & Services sector and 100.91% lower than that of the Health Care industry. The working capital for all United States stocks is 100.28% higher than that of the company.
Interpace Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Interpace Biosciences' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Interpace Biosciences could also be used in its relative valuation, which is a method of valuing Interpace Biosciences by comparing valuation metrics of similar companies.Interpace Biosciences is currently under evaluation in working capital category among its peers.
Interpace Fundamentals
| Return On Equity | -2.85 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.28) % | ||||
| Current Valuation | 11.72 M | ||||
| Shares Outstanding | 4.27 M | ||||
| Shares Owned By Insiders | 28.12 % | ||||
| Number Of Shares Shorted | 47.35 K | ||||
| Price To Earning | (1.07) X | ||||
| Price To Book | 10.04 X | ||||
| Price To Sales | 0.10 X | ||||
| Revenue | 41.31 M | ||||
| Gross Profit | 17.95 M | ||||
| EBITDA | (9.12 M) | ||||
| Net Income | (14.94 M) | ||||
| Cash And Equivalents | 1.86 M | ||||
| Cash Per Share | 0.44 X | ||||
| Total Debt | 9.44 M | ||||
| Debt To Equity | 6.55 % | ||||
| Current Ratio | 0.61 X | ||||
| Book Value Per Share | (14.51) X | ||||
| Cash Flow From Operations | (8.72 M) | ||||
| Short Ratio | 0.19 X | ||||
| Earnings Per Share | (3.12) X | ||||
| Target Price | 11.0 | ||||
| Number Of Employees | 147 | ||||
| Beta | 0.82 | ||||
| Market Capitalization | 5.16 M | ||||
| Total Asset | 38.43 M | ||||
| Retained Earnings | (172.59 M) | ||||
| Working Capital | (4.21 M) | ||||
| Current Asset | 19.16 M | ||||
| Current Liabilities | 23.37 M | ||||
| Z Score | -4.6 | ||||
| Net Asset | 38.43 M |
About Interpace Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Interpace Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Interpace Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Interpace Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in Interpace OTC Stock
If you are still planning to invest in Interpace Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Interpace Biosciences' history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |